Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.67 |
| ▸ | NPC1 | O15118 | 9/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | SCN4A | P35499 | 2/20 | 0.63 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17455087 | 0.98 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2SCN4ASCN9A | |
| SCHEMBL3216411 | 0.94 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2SCN4ASCN9A | |
| SCHEMBL8526236 | 0.84 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL1713549 | 0.83 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL7217567 | 0.83 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL11783793 | 0.83 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL29561851 | 0.81 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL2202283 | 0.81 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL9571707 | 0.81 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL20767885 | 0.81 | SCN4A (0.67) | RAB9ANPC1SMN1; SMN2SCN4ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430626-A | Tridurum boron skeleton compound PPB1 and preparation method and application thereof | 湖南科技大学 | 2024-01-23 | — | — | CN | claimed |
| CN-1894259-A | Rifamycin analogs and uses thereof | ACTIVBIOTICS INC (US) | 2007-01-10 | — | — | CN | claimed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| JP-11199573-A | — | — | None | — | — | JP | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| CN-118159530-A | Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling | 康福治疗有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4377307-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | Confo Therapeutics N.V. (BE) | 2024-06-05 | — | — | EP | disclosed |
| CN-117430626-A | Tridurum boron skeleton compound PPB1 and preparation method and application thereof | 湖南科技大学 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023006893-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | CONFO THERAPEUTICS N.V. (BE) | 2023-02-02 | — | — | WO | disclosed |
| US-4780466-A | ANALGESICS, ANTIPSYCHOTIC AGENTS, ANXIOLYTIC AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-10-25 | — | — | US | disclosed |
| US-4742059-A | ANTIASTMA, ANTIALLERGENS | AMERICAN CYANAMIDE COMPANY (US) | 1988-05-03 | — | — | US | disclosed |
| EP-0263213-A1 | C20 Through C26 amino steroids | THE UPJOHN COMPANY (US) | 1988-04-13 | — | — | EP | disclosed |
| EP-0238545-A1 | C 20? THROUGH C 26? AMINO STEROIDS. | UPJOHN CO (US) | 1987-09-30 | — | — | EP | disclosed |
| US-4692449-A | ANTIASTHMATIC AND ANTIALLERGIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| WO-1987001706-A2 | C20 THROUGH C26 AMINO STEROIDS | THE UPJOHN COMPANY (US) | 1987-03-26 | — | — | WO | disclosed |
| CN-86106226-A | 20-and 21-amino steroids | — | 1987-03-18 | — | — | CN | disclosed |
| US-4112092-A | CNS DISORDER, PARKINSON'S, CARDIOVASCULAR DISORDER | SCIENCE UNION ET CIE (FR) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | AGTR2, AGTR1, OPRL1 | RAB9A 2496/4885NPC1 1380/4885SMN1; SMN2 1716/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | RAB9A 2925/4885NPC1 125/4885SMN1; SMN2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.